Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Levin MJ, et al. Among authors: beavon r. N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20. N Engl J Med. 2022. PMID: 35443106 Free PMC article. Clinical Trial.
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; COVID-19 Study to Optimally Reduce Morbidity in CareHomes and Sites with Enhanced Risk (STORMCHASER) Study Group. Levin MJ, et al. Among authors: beavon r. Clin Infect Dis. 2023 Apr 3;76(7):1247-1256. doi: 10.1093/cid/ciac899. Clin Infect Dis. 2023. PMID: 36411267 Free PMC article. Clinical Trial.
Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2.
Mitsi E, Reiné J, Urban BC, Solórzano C, Nikolaou E, Hyder-Wright AD, Pojar S, Howard A, Hitchins L, Glynn S, Farrar MC, Liatsikos K, Collins AM, Walker NF, Hill HC, German EL, Cheliotis KS, Byrne RL, Williams CT, Cubas-Atienzar AI, Fletcher TE, Adams ER, Draper SJ, Pulido D, Beavon R, Theilacker C, Begier E, Jodar L, Gessner BD, Ferreira DM. Mitsi E, et al. Among authors: beavon r. J Clin Invest. 2022 Apr 1;132(7):e157124. doi: 10.1172/JCI157124. J Clin Invest. 2022. PMID: 35139037 Free PMC article.
Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018.
Njuma Libwea J, Fletcher MA, Koki Ndombo P, Boula A, Ashukem NT, Ngo Baleba M, Kingue Bebey RS, Nkolo Mviena EG, Tageube J, Kobela Mbollo M, Koulla-Shiro S, Madhi S, Njanpop-Lafourcade BM, Mohammad A, Begier E, Southern J, Beavon R, Gessner B. Njuma Libwea J, et al. Among authors: beavon r. PLoS One. 2021 Apr 15;16(4):e0250010. doi: 10.1371/journal.pone.0250010. eCollection 2021. PLoS One. 2021. PMID: 33857235 Free PMC article.
Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study.
von Mollendorf C, Ulziibayar M, Gessner BD, Do LAH, Nguyen CD, Beavon R, Suuri B, Luvsantseren D, Narangerel D, Jenney A, Dunne EM, Satzke C, Darmaa B, Mungun T, Mulholland EK. von Mollendorf C, et al. Among authors: beavon r. BMC Public Health. 2021 Sep 23;21(1):1731. doi: 10.1186/s12889-021-11776-8. BMC Public Health. 2021. PMID: 34556065 Free PMC article.
Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A, Konstantinidis A, Kossyvaki V, Skiadas J, Menegas D, Méndez C, Beavon R, Begier E, Gessner BD, Milionis H, Tsimihodimos V, Baxevanos G, Argiriadou T, Terrovitou C, Toumbis M; EGNATIA Study Group. Liapikou A, et al. Among authors: beavon r. Hum Vaccin Immunother. 2022 Nov 30;18(5):2079923. doi: 10.1080/21645515.2022.2079923. Epub 2022 Jun 15. Hum Vaccin Immunother. 2022. PMID: 35703733 Free PMC article.
Human Infection Challenge with Serotype 3 Pneumococcus.
Robinson RE, Mitsi E, Nikolaou E, Pojar S, Chen T, Reiné J, Nyazika TK, Court J, Davies K, Farrar M, Gonzalez-Dias P, Hamilton J, Hill H, Hitchins L, Howard A, Hyder-Wright A, Lesosky M, Liatsikos K, Matope A, McLenaghan D, Myerscough C, Murphy A, Solórzano C, Wang D, Burhan H, Gautam M, Begier E, Theilacker C, Beavon R, Anderson AS, Gessner BD, Gordon SB, Collins AM, Ferreira DM. Robinson RE, et al. Among authors: beavon r. Am J Respir Crit Care Med. 2022 Dec 1;206(11):1379-1392. doi: 10.1164/rccm.202112-2700OC. Am J Respir Crit Care Med. 2022. PMID: 35802840
Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016-2018-The ECAPS study.
Hansen K, Rünow E, Torisson G, Theilacker C, Palmborg A, Pan K, Jiang Q, Southern J, Beavon R, Gessner BD, Riesbeck K, Ahl J. Hansen K, et al. Among authors: beavon r. Front Public Health. 2023 Feb 17;11:1086648. doi: 10.3389/fpubh.2023.1086648. eCollection 2023. Front Public Health. 2023. PMID: 36875379 Free PMC article.
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Levin MJ, Ustianowski A, De Wit S, Beavon R, Thissen J, Seegobin S, Dey K, Near KA, Streicher K, Kiazand A, Esser MT. Levin MJ, et al. Among authors: beavon r. Infect Dis Ther. 2024 May 4. doi: 10.1007/s40121-024-00970-x. Online ahead of print. Infect Dis Ther. 2024. PMID: 38703336
11 results